© COPYRIGHT 2023 IMAGEN THERAPEUTICS LTD.
Company Registered in England & Wales No. 06373341
Non–small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide. Despite remarkably high response rates to first line small molecule tyrosine kinase inhibitors (TKI) targeting the epidermal growth receptor (EGFR) or the anaplastic lymphoma kinase (ALK), the majority of patients develop resistance.
There is an unmet need to develop novel clinically relevant preclinical models of NSCLC that recapitulate the biology of the patient tumour for biomarker discovery and to accelerate the identification of novel drug targets and better combination treatments.
Our PDC models represent a unique patient-derived system amenable to the investigation of your small molecule efficacy and to the evaluation of novel combination strategies. Benefit from:
|Model ID||Cancer type||PDC genotype||Patient treatment data|
|PTX-0479||Lung adenocarcinoma||EGFR G179C/S768I||Contact us to see all model data|
|PTX-0480||Lung adenocarcinoma||EGFR exon19del|
|PTX-0481||Lung adenocarcinoma||EGFR exon20ins(S768_D770dup), TP53 mutation (p.R280T)|
|PTX-0482||Lung adenocarcinoma||EGFR exon19del/T790M/C797S|
|PTX-0483||Lung adenocarcinoma||EGFR L858R|
|PTX-0485||Lung adenocarcinoma||EGFR L861Q|
|PTX-0488||Lung adenocarcinoma||EGFR L858R|
NSCLC Targeted Screen
Identify novel therapeutic targets and combination strategies to overcome EGFRi and ALKi resistance in patients
Choose up to 50 PDC models to enroll in our pan-cancer screen
Discover what Imagen can do for your drug development program, at any stage
Find out how PDC model can be applied as a tool for drug discovery and development